EGFR基因突变非小细胞肺癌药物治疗对心脏影响  

Cardiac effects of drug therapy for non-small cell lung cancer with EGFR gene mutation

作　　者：胡雅宁 陈传军 刘元生[2] 曲涛 Hu yaning;Chen chuanjun;Liu yuansheng;Qu tao(The Third Afilied Hospital of Inner Mongolia Medical Unriversity,Baotou,014010,China;Prhing University People's Hospital,Beijing,00044,China)

机构地区：[1]内蒙古包钢医院/内蒙古医科大学第三附属医院,014010 [2]北京大学人民医院,100044

出　　处：《临床心电学杂志》2024年第3期206-210,共5页Journal of Clinical Electrocardiology

摘　　要：非小细胞肺癌(Non-small-cell carcinoma,NSCLC)约占肺癌患者的85%,且发病率逐年增加,而分子靶向治疗的快速发展为晚期非小细胞肺癌的患者带来了希望。其中,表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗非小细胞肺癌期间不可避免地会出现不同程度的心血管毒性。临床上在治疗非小细胞肺癌的同时,关注EGFR-TKI所致的心血管毒性是必要的。本文就EGFR-TKI治疗晚期非小细胞肺癌所导致的心血管毒性做出分析,以探索基于免疫疗法抑制剂治疗EGFR-TKI耐药非小细胞肺癌患者的重要临床研究,为更好地治愈非小细胞肺癌,并防治相关并发症提供参考。Non-small cell lung cancer(NSCLC)accounts for about 85%of lung cancer patients,and the incidence is increasing year by year,while the rapid development of molecular targeted therapy has brought hope to patients with advanced non-small cell lung cancer.Among them,epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKI)in the treatment of non-small cell lung cancer will inevitably appear different degrees of cardiovascular toxicity.It is necessary to pay attention to the cardiovascular toxicity caused by EGFR-TKI in the treatment of non-small cell lung cancer.This paper analyzes the cardiovascular toxicity caused by EGFR-TKI in the treatment of advanced non-small cell lung cancer,and explores the important clinical studies based on immunotherapy inhibitors in the treatment of EGFR-TKI resistant NSCLC patients,so as to provide references for better cure of non-small cell lung cancer and prevention and treatment of related complications.

关 键 词：心血管毒性 表皮生长因子酪氨酸激酶抑制剂 非小细胞肺癌 肿瘤心脏病 

分 类 号：R541.7[医药卫生—心血管疾病] R540.41[医药卫生—内科学]